214 related articles for article (PubMed ID: 10731973)
41. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
[TBL] [Abstract][Full Text] [Related]
42. [Long-term infusion of L-asparaginase--an alternative to intramuscular injection?].
Rodriguez T; Baumgarten E; Fengler R; Soumpasis D; Henze G
Klin Padiatr; 1995; 207(4):207-10. PubMed ID: 7564153
[TBL] [Abstract][Full Text] [Related]
43. [Acquired deficiencies in antithrombin III and C protein during treatment with L-asparaginase].
Mielot F; Danel P; Boyer C; Coulombel L; Dommergues JP; Tchernia G; Larrieu MJ
Arch Fr Pediatr; 1987 Mar; 44(3):161-5. PubMed ID: 2883953
[TBL] [Abstract][Full Text] [Related]
44. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
45. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
Top PC; Tissing WJ; Kuiper JW; Pieters R; van Eijck CH
Pediatr Blood Cancer; 2005 Jan; 44(1):95-7. PubMed ID: 15368548
[TBL] [Abstract][Full Text] [Related]
46. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
47. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
48. [Superior sagittal sinus thrombosis following L-asparaginase therapy of acute lymphoblastic leukemia].
Watanabe I; Sakai I; Matsumoto I
Rinsho Ketsueki; 1992 Mar; 33(3):343-8. PubMed ID: 1578639
[TBL] [Abstract][Full Text] [Related]
49. Greater decrease of fibrinogen as compared to antithrombin III in L-asparaginase treated leukemia patients.
Vicarioto M; Rosolen A; Cappellato MG; Zanesco L; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(5):663-9. PubMed ID: 2435632
[TBL] [Abstract][Full Text] [Related]
50. Correction of hemostatic imbalances induced by L-asparaginase therapy in children with acute lymphoblastic leukemia.
Zaunschirm A; Muntean W
Pediatr Hematol Oncol; 1986; 3(1):19-25. PubMed ID: 3153215
[TBL] [Abstract][Full Text] [Related]
51. Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia.
Ishihara T; Nogami K; Ochi S; Ishida T; Kosaka Y; Sawada A; Inoue M; Osone S; Imamura T; Hosoi H; Shima M
Pediatr Blood Cancer; 2020 Jan; 67(1):e28016. PubMed ID: 31556233
[TBL] [Abstract][Full Text] [Related]
52. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
53. [Cerebral thrombosis in a child with acute lymphocytic leukemia during L-asparaginase therapy].
Horigome Y; Hanada T; Inudoh M; Takita H
Rinsho Ketsueki; 1989 Aug; 30(8):1284-8. PubMed ID: 2601047
[TBL] [Abstract][Full Text] [Related]
54. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study.
Mazzucconi MG; Gugliotta L; Leone G; Dragoni F; Belmonte MM; De Stefano V; Chistolini A; Tura S; Mandelli F
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):23-8. PubMed ID: 7514043
[TBL] [Abstract][Full Text] [Related]
55. [Hyperglycemia as a side effect of using L-asparaginase in children with acute lymphoblastic leukemia (ALL].
Brodkiewicz A; Kamieńska E; Urasiński T; Peregud-Pogorzelski J
Acta Haematol Pol; 1995; 26(1):99-101. PubMed ID: 7747569
[TBL] [Abstract][Full Text] [Related]
56. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
[TBL] [Abstract][Full Text] [Related]
57. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Yang L; Panetta JC; Cai X; Yang W; Pei D; Cheng C; Kornegay N; Pui CH; Relling MV
J Clin Oncol; 2008 Apr; 26(12):1932-9. PubMed ID: 18421047
[TBL] [Abstract][Full Text] [Related]
58. Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?
Tokimasa S; Yamato K
Br J Haematol; 2012 May; 157(3):381-2. PubMed ID: 22145577
[No Abstract] [Full Text] [Related]
59. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
[TBL] [Abstract][Full Text] [Related]
60. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
